Organigram Global Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $118.3M-0.9% YoYTTM through 30 Sep 2024
Net Income -$33.6MTTM through 30 Sep 2024
Free Cash Flow -$635KTTM through 30 Sep 2024
Margins
| Current | |
|---|---|
| Gross Margin | 25.1% |
| EBITDA Margin | -19.9% |
| Operating Margin | -22.3% |
| Net Margin | -28.4% |
Returns
-12.2%ROE
-8.7%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio2.82x
Net Debt-$54.8Mnet cash position
Cash & Equivalents$54.8M
Quality Metrics
Piotroski F-Score2 / 9
FCF Margin-0.5%
Earnings-Beat Rate33.3%
Dividend
No dividend
Capital Allocation
Capex Intensity4.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Recreational Cannabis | $50M | -11.7% | View detailsFacing temporary competitive and operational challenges in vapes and infused pre-rolls, which are being addressed through operational remediation. |
| International Wholesale | $6.1M | 0.0% | View detailsExpected to see a material step change in growth in the second half of Fiscal 2026, supported by the consolidation of Sanity Group starting in Q3. |
Financials converted at 1.3527 from CAD.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.